These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22634354)

  • 1. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Warner B; Harris AW
    Gastroenterology; 2012 Jul; 143(1):e42; author reply e42. PubMed ID: 22634354
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
    Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab in active ulcerative colitis: a "real-life" observational study.
    ; Armuzzi A; Biancone L; Daperno M; Coli A; Pugliese D; Annese V; Aratari A; Ardizzone S; Balestrieri P; Bossa F; Cappello M; Castiglione F; Cicala M; Danese S; D'Incà R; Dulbecco P; Feliciangeli G; Fries W; Genise S; Gionchetti P; Gozzi S; Kohn A; Lorenzetti R; Milla M; Onali S; Orlando A; Papparella LG; Renna S; Ricci C; Rizzello F; Sostegni R; Guidi L; Papi C
    Dig Liver Dis; 2013 Sep; 45(9):738-43. PubMed ID: 23683530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis.
    Andrisani G; Gremese E; Guidi L; Papa A; Marzo M; Felice C; Pugliese D; Armuzzi A
    Reumatismo; 2013 May; 65(2):75-8. PubMed ID: 23877411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab.
    Armuzzi A; Pugliese D; Nardone OM; Guidi L
    Drug Des Devel Ther; 2013; 7():289-96. PubMed ID: 23630414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.
    Burness CB; Keating GM
    BioDrugs; 2013 Jun; 27(3):247-62. PubMed ID: 23580096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
    Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
    Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?
    Roblin X; Paul S
    J Crohns Colitis; 2024 Mar; 18(3):337-338. PubMed ID: 37847799
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
    Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
    Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active ulcerative colitis diagnosed by (18)F-FDG PET/CT in an anti-TNF alpha treated patient with no visible luminal lesions on colonoscopy.
    Parbo P; Stribolt K; Rittig CS; Gormsen LC
    Int J Colorectal Dis; 2014 May; 29(5):643-4. PubMed ID: 24531694
    [No Abstract]   [Full Text] [Related]  

  • 16. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vedolizumab for the treatment of ulcerative colitis.
    Stallmach A; Schmidt C; Teich N
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):165-75. PubMed ID: 26588993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Kim JH; Cheon JH
    Gut Liver; 2016 Mar; 10(2):162-3. PubMed ID: 26934881
    [No Abstract]   [Full Text] [Related]  

  • 19. [Golimumab Therapy in Ulcerative Colitis].
    Moon W
    Korean J Gastroenterol; 2016 Feb; 67(2):64-73. PubMed ID: 26907481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis.
    Busquets D; Aldeguer X
    J Crohns Colitis; 2013 Jun; 7(5):e195. PubMed ID: 23219261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.